Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Multivariate analysis of time to CNS metastases adjusted for non-CNS metastases as competing risk

From: Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto

Parameter Hazard ratio 95% hazard ratio confidence limits Significance level
Analysis without consideration of pCR rate
 Age (continuous) 1.001 0.984–1.018 p = 0.9359
 Tumor size (cT3–4) (reference category: cT1–2) 1.830 1.223–2.737 p = 0.0033
 Node-positive disease (reference category: node-negative disease) 2.681 1.710–4.205 p < 0.0001
 Luminal B-like subtype (reference category: luminal A-like subtype) 1.573 0.611–4.053 p = 0.3478
 HER2-positive subtype (reference category: luminal A-like subtype) 3.357 1.673–6.736 p = 0.0007
 Triple-negative subtype (reference category: luminal A-like subtype) 5.569 2.882–10.758 p < 0.0001
Analysis with consideration of pCR rate
 Age (continuous) 0.999 0.981–1.016 p = 0.8813
 Tumor size (cT3–4) (reference category: cT1–2) 1.626 1.075–2.458 p = 0.0213
 Node-positive disease (reference category: node-negative disease) 2.574 1.641–4.037 p < 0.0001
 Luminal B-like subtype (reference category: luminal A-like subtype) 1.617 0.627–4.171 p = 0.3200
 HER2-positive subtype (reference category: luminal A-like subtype) 3.804 1.894–7.639 p = 0.0002
 Triple-negative subtype (reference category: luminal A-like subtype) 6.384 3.277–12.440 p < 0.0001
 No pCR after neoadjuvant chemotherapy (reference category: pCR after neoadjuvant chemotherapy) 2.294 1.324–3.973 p = 0.0031